Fluorodeoxyglucose–Positron-Emission Tomography Imaging of Head and Neck Squamous Cell Cancer

References

1. 1.↵
   1. Carvalho A,
   2. Nishimoto I,
   3. Califano J,
   4. et al

   . Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806–16

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Canto MT,
   2. Devesa SS

   . Oral cavity and pharynx cancer incidence rates in the United States, 1975–1998. Oral Oncol 2002; 38: 610–17

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Forastiere A,
   2. Koch W,
   3. Trotti A,
   4. et al

   . Head and neck cancer. N Engl J Med 2001; 345: 1890–900

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Cooper JS,
   2. Pajak TF,
   3. Forastiere AA,
   4. et al

   . Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937–44

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Bernier J,
   2. Domenge C,
   3. Ozsahin M,
   4. et al

   . Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945–52

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Whitehurst J,
   2. Droulias C

   . Surgical treatment of squamous cell carcinoma of the oral tongue: factors influencing survival. Arch Otolaryngol 1977; 103: 212–15

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Snow G,
   2. Annyas A,
   3. van Slooten E,
   4. et al

   . Prognostic factors of neck node metastases. Clin Otolaryngol 1982; 7: 185–92

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Czernin J,
   2. Schelbert H

   . PET/CT imaging: facts, opinions, hopes, and questions. J Nucl Med 2004; 45: S1–3S

   FREE Full Text
9. 9.↵
   1. Beyer T,
   2. Antoch G,
   3. Muller S,
   4. et al

   . Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 2004; 45: 25S–35S

   Abstract/FREE Full Text
10. 10.↵
    1. Wong T,
    2. Paulson E,
    3. Nelson R,
    4. et al

    . Practical approach to diagnostic CT combined with PET. AJR Am J Roentgenol 2007; 188: 622–29

    CrossRefPubMed
11. 11.↵
    1. Kole A,
    2. Nieweg O,
    3. Pruim J,
    4. et al

    . Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82: 1160–66

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Johansen J,
    2. Eigtved A,
    3. Buchwald C,
    4. et al

    . Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope 2002; 112: 2009–14

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Jungehulsing M,
    2. Scheidhauer K,
    3. Damm M,
    4. et al

    . 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000; 123: 294–301

    Abstract/FREE Full Text
14. 14.↵
    1. Aassar OS,
    2. Fischbein NJ,
    3. Caputo GR,
    4. et al

    . Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999; 210: 177–81

    PubMedWeb of Science
15. 15.↵
    1. Rusthoven K,
    2. Koshy M,
    3. Paulino A

    . The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004; 101: 2641–49

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Johansen J,
    2. Buus S,
    3. Loft A,
    4. et al

    . Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor: results from the DAHANCA-13 study. Head Neck 2008; 30: 471–78

    CrossRefPubMed
17. 17.↵
    1. Nassenstein K,
    2. Veit-Haibach P,
    3. Stergar H,
    4. et al

    . Cervical lymph node metastases of unknown origin: primary tumor detection with whole-body positron emission tomography/computed tomography. Acta Radiol 2007 Oct 23: 1–8 [Epub ahead of print]
18. 18.↵
    1. Miller F,
    2. Karnad A,
    3. Eng T,
    4. et al

    . Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. Head Neck 2008; 30: 28–34

    CrossRefPubMed
19. 19.↵
    1. Wong W,
    2. Chevretton E,
    3. McGurk M,
    4. et al

    . A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 1997; 22: 209–14

    CrossRefPubMed
20. 20.↵
    1. Ha P,
    2. Hdeib A,
    3. Goldenberg D,
    4. et al

    . The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132: 12–16

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Layland M,
    2. Sessions D,
    3. Lenox J

    . The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope 2005; 115: 629–39

    CrossRefPubMed
22. 22.↵
    1. Curtin H,
    2. Ishwaran H,
    3. Mancuso A,
    4. et al

    . Comparison of CT and MR imaging in staging of neck metastases. Radiology 1998; 207: 123–30

    PubMedWeb of Science
23. 23.↵
    1. van den Brekel M,
    2. Stel H,
    3. Castelijns J,
    4. et al

    . Cervical lymph node metastasis: assessment of radiologic criteria. Radiology 1990; 177: 379–84

    PubMedWeb of Science
24. 24.↵
    1. Sakai O,
    2. Curtin H,
    3. Romo L,
    4. et al

    . Lymph node pathology: benign proliferative, lymphoma, and metastatic disease. Radiol Clin North Am 2000; 38: 979–98

    CrossRefPubMed
25. 25.↵
    1. Schmid D,
    2. Stoeckli S,
    3. Bandhauer F,
    4. et al

    . Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003; 113: 888–91

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Schwartz D,
    2. Rajendran J,
    3. Yueh B,
    4. et al

    . Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg 2003; 129: 1173–78

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Schoder H,
    2. Yeung H

    . Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 2004; 34: 180–97

    CrossRefPubMed
28. 28.↵
    1. Braams J,
    2. Pruim J,
    3. Freling N,
    4. et al

    . Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995; 36: 211–16

    Abstract/FREE Full Text
29. 29.↵
    1. Murakami R,
    2. Uozumi H,
    3. Hirai T,
    4. et al

    . Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007; 68: 377–82. Epub 2007 Feb 22

    PubMed
30. 30.↵
    1. Ryan W,
    2. Fee WJ,
    3. Le Q,
    4. et al

    . Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115: 645–50

    PubMedWeb of Science
31. 31.↵
    1. Manolidis S,
    2. Donald P,
    3. Volk P,
    4. et al

    . The use of positron emission tomography scanning in occult and recurrent head and neck cancer. Acta Otolaryngol Suppl 1998; 534: 1–11

    PubMed
32. 32.↵
    1. Brouwer J,
    2. Senft A,
    3. de Bree R,
    4. et al

    . Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol 2006; 42: 275–80

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Vogel W,
    2. Schinagl D,
    3. Van Dalen J,
    4. et al

    . Validated image fusion of dedicated PET and CT for external beam radiation and therapy in the head and neck area. Q J Nucl Med Mol Imaging 2008; 2008: 74–83
34. 34.↵
    1. Lee NY,
    2. Mechalakos JG,
    3. Nehmeh S,
    4. et al

    . Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2008; 70: 2–13. Epub 2007 Sep 14

    PubMed
35. 35.↵
    1. Ford E,
    2. Kinahan P,
    3. Hanlon L,
    4. et al

    . Tumor delineation using PET in head and neck cancers: threshold contouring and lesion volumes. Med Phys 2006; 33: 4280–88

    CrossRefPubMed
36. 36.↵
    1. Lowe V,
    2. Hebert M,
    3. Anscher M,
    4. et al

    . Serial evaluation of increased chest wall F-18 fluorodeoxyglucose (FDG) uptake following radiation therapy in patients with bronchogenic carcinoma. Clin Positron Imaging 1998; 1: 185–91

    CrossRefPubMed
37. 37.↵
    1. Andrade RS,
    2. Heron DE,
    3. Degirmenci B,
    4. et al

    . Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006; 65: 1315–22

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Porceddu S,
    2. Jarmolowski E,
    3. Hicks R,
    4. et al

    . Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 2005; 27: 175–81

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Quon A,
    2. Fischbein NJ,
    3. McDougall IR,
    4. et al

    . Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med 2007; 48: 58S–67S

    Abstract/FREE Full Text
40. 40.↵
    1. Kitagawa Y,
    2. Nishizawa S,
    3. Sano K,
    4. et al

    . Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 2003; 44: 198–206

    Abstract/FREE Full Text
41. 41.↵
    1. Goerres GW,
    2. Schmid DT,
    3. Bandhauer F,
    4. et al

    . Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130: 105–09

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Klabbers BM,
    2. Lammertsma AA,
    3. Slotman BJ

    . The value of positron emission tomography for monitoring response to radiotherapy in head and neck cancer. Mol Imaging Biol 2003; 5: 257–70

    CrossRefPubMed
43. 43.↵
    1. Brkovich V,
    2. Miller F,
    3. Karnad A,
    4. et al

    . The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. Laryngoscope 2006; 116: 855–58

    PubMedWeb of Science
44. 44.↵
    1. Kubota K,
    2. Yokoyama J,
    3. Yamaguchi K,
    4. et al

    . FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging 2004; 31: 590–95

    CrossRefPubMedWeb of Science
45. 45.↵
    1. Yao M,
    2. Graham MM,
    3. Hoffman HT,
    4. et al

    . The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004; 59: 1001–10

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Yao M,
    2. Buatti JM,
    3. Dornfeld KJ,
    4. et al

    . Can post-RT FDG PET accurately predict the pathologic status in neck dissection after radiation for locally advanced head and neck cancer? In regard to Rogers, et al. (Int J Radiat Oncol Biol Phys 2004;58:694–97). Int J Radiat Oncol Biol Phys 2005; 61: 306–07, author reply 307

    PubMedWeb of Science
47. 47.↵
    1. Anzai Y,
    2. Carroll WR,
    3. Quint DJ,
    4. et al

    . Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996; 200: 135–41

    PubMed
48. 48.↵
    1. Kao CH,
    2. ChangLai SP,
    3. Chieng PU,
    4. et al

    . Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol 1998; 16: 3550–55

    Abstract
49. 49.↵
    1. Lowe VJ,
    2. Boyd JH,
    3. Dunphy FR,
    4. et al

    . Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18: 651–58

    Abstract/FREE Full Text
50. 50.↵
    1. Fischbein NJ,
    2. Aassar OS,
    3. Caputo GR,
    4. et al

    . Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. AJNR Am J Neuroradiol 1998; 19: 1189–96

    Abstract
51. 51.↵
    1. Wong RJ,
    2. Lin DT,
    3. Schoder H,
    4. et al

    . Diagnostic and prognostic value of [18F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20: 4199–208

    Abstract/FREE Full Text
52. 52.↵
    1. Yao M,
    2. Luo P,
    3. Hoffman H,
    4. et al

    . Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment. Am J Clin Oncol 2007; 30: 264–70

    CrossRefPubMedWeb of Science
53. 53.↵
    1. Gourin C,
    2. Williams H,
    3. Seabolt W,
    4. et al

    . Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope 2006; 116: 705–10

    CrossRefPubMedWeb of Science